Cargando…

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis

Mostrar otras versiones (1)

In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in standard clinical practice with the aim of evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holmsten, Karin, Dohn, Line, Jensen, Niels Viggo, Shah, Carl-Henrik, Jäderling, Fredrik, Pappot, Helle, Ullén, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950730/ https://www.ncbi.nlm.nih.gov/pubmed/27446429 http://dx.doi.org/10.3892/ol.2016.4775

Ejemplares similares

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2017)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
por: Bernardini, Alejandra, et al.
Publicado: (2022)

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome
por: Viktorsson, Kristina, et al.
Publicado: (2022)

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
por: Morel, Armand, et al.
Publicado: (2010)

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
por: Riedel, Felix, et al.
Publicado: (2022)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience
por: Retz, Margitta, et al.
Publicado: (2015)

Optimal Systemic Treatment of Advanced Bladder Cancer—A Moving Target
por: Pappot, Helle, et al.
Publicado: (2020)

Optimal Systemic Treatment of Advanced Bladder Cancer Calls for a Multidisciplinary Approach
por: Pappot, Helle, et al.
Publicado: (2023)

The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial
por: Taarnhøj, Gry Assam, et al.
Publicado: (2023)

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
por: Passalacqua, Rodolfo, et al.
Publicado: (2017)

Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
por: Médioni, Jacques, et al.
Publicado: (2016)

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study
por: Omland, Lise H., et al.
Publicado: (2020)

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy
por: Brousell, Steven C, et al.
Publicado: (2018)

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
por: De Santis, M., et al.
Publicado: (2016)

Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma
por: Font, Albert, et al.
Publicado: (2021)

Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy – a feasibility study
por: Taarnhøj, Gry Assam, et al.
Publicado: (2020)

Vinflunine in the treatment of bladder cancer
por: Bachner, Mark, et al.
Publicado: (2008)

uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder – Possible Clinical Implications
por: Dohn, Line Hammer, et al.
Publicado: (2015)

Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group
por: Pistamaltzian, Nikolaos, et al.
Publicado: (2016)

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
por: Castellano, Daniel, et al.
Publicado: (2014)

From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples
por: Facchini, Gaetano, et al.
Publicado: (2016)

Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder
por: Dohn, Line H., et al.
Publicado: (2021)

Stathmin Potentiates Vinflunine and Inhibits Paclitaxel Activity
por: Malesinski, Soazig, et al.
Publicado: (2015)

Electronic symptom monitoring in patients with metastatic lung cancer: a feasibility study
por: Friis, Rasmus Blechingberg, et al.
Publicado: (2020)

The long-term course of fatigue following breast cancer diagnosis
por: Biering, Karin, et al.
Publicado: (2020)

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report
por: Bordi, Paola, et al.
Publicado: (2016)

VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
por: Nicholson, Steve, et al.
Publicado: (2021)

VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland
por: Hussain, Syed A., et al.
Publicado: (2017)

PD‐L1 expression and FGFR‐mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study
por: Grantzau, Trine, et al.
Publicado: (2022)

Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro
por: Simoens, Cindy, et al.
Publicado: (2008)

Anthelmintic resistance. An overview of the situation in the Nordic countries
por: Ihler, Carl Fredrik
Publicado: (2010)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
por: Fradet, Y, et al.
Publicado: (2019)

Lateralization in cluster headache: a Nordic multicenter study
por: Meyer, Eva Laudon, et al.
Publicado: (2009)

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
por: Holwell, S E, et al.
Publicado: (2001)

Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience
por: Taarnhøj, Gry Assam, et al.
Publicado: (2021)

Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development
por: Kruczynski, A, et al.
Publicado: (2002)

Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
por: Tolstrup, Lærke K., et al.
Publicado: (2019)

Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients’ and Clinicians’ Experiences
por: Tolstrup, Lærke K, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pehcu72tneujh2ek8k410sj6bm